Hematologic Oncology | Specialty

Expert Describes Importance of Classifying T-Cell Lymphomas

October 28th 2016

Novel agents being explored in the landscape of both peripheral and cutaneous T-cell lymphomas could lead to an expansion of treatment options for patients.

New Data Sustain Strong Benefit for Nivolumab in Hodgkin Lymphoma

October 26th 2016

Updated results from the CheckMate-205 trial showed that nivolumab had an objective response rate of 73% in a cohort of patients with classical Hodgkin lymphoma who received brentuximab vedotin before and/or after autologous hematopoietic stem cell transplantation.

Dr. Mesa on NCCN Guidelines for MPNs

October 26th 2016

Ruben A. Mesa, MD, chair, Division of Hematology and Medical Oncology, deputy director, professor of Medicine, Mayo Clinic, discusses the NCCN guidelines for treatment of patients with myeloproliferative neoplasms (MPNs).

Ponatinib (CML) Pricing Gets a Blast From Congress

October 21st 2016

The latest company to suffer a public relations and stock price crisis based on its drug pricing strategy is Ariad Pharmaceuticals, which has been blasted by Sen. Bernard Sanders (I-VT) on Twitter and in a formal letter demanding justification for the price tag Ariad has attached to the chronic myelogenous leukemia drug ponatinib.

Dr. Reeder on Evolving Role of R-CHOP in Aggressive Lymphomas

October 20th 2016

Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses the role that R-CHOP will continue to have in the treatment of patients with aggressive lymphomas.

Dr. Rosenthal on Treatment Strategies for Indolent Lymphomas

October 20th 2016

Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses some of the treatment strategies for patients with indolent lymphomas.

CHMP Issues Positive Opinion for Nivolumab in Hodgkin Lymphoma

October 14th 2016

The Committee for Medicinal Products for Human Use has recommended approval of nivolumab for the treatment of patients with relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin.

Moving Beyond R-CHOP in Large Cell Lymphoma

October 14th 2016

Patients with large cell lymphomas have a standard approach of R-CHOP; however, those who fall under the activated B-cell-like (ABC) subtype are not likely to respond well to the regimen.

New Patient Subsets, Emerging Therapies Advance ALL Care

October 13th 2016

Increasing subsets of patients—both adult and pediatric—with acute lymphoblastic leukemia are being administered therapies designed to target their molecular subtypes, according to Elias Joseph Jabbour, MD.

Dr. Jerald P. Radich on Treatment Considerations with Generic Imatinib in CML

October 8th 2016

​Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses which patients should receive the newly approval generic imatinib versus second-generation tyrosine-kinase inhibitors (TKIs) in chronic myeloid leukemia (CML).

Dr. Ruben Mesa on Impact of New NCCN Guidelines for MPN

October 8th 2016

Ruben Mesa, MD chair, hematology Mayo Clinic, MPN, discusses the significance of the new National Comprehensive Cancer Network (NCCN) guidelines for myeloproliferative neoplasms (MPN).

Erin Kopp on the Toxicities of Cutaneous T-cell Lymphoma Treatment

October 6th 2016

Erin Kopp, ACNP-BC, City of Hope Comprehensive Cancer Center, on managing the side effects of cutaneous T-cell lymphoma treatment.

Dr. Richard M. Stone on the Genetic Landscape in AML

October 6th 2016

​Richard M. Stone, MD, chief of staff, program director, adult leukemia, institute physician, professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses what is currently understood regarding the genetic landscape in acute myeloid leukemia (AML).

Dr. Horwitz on Combination CHOP Regimens in Peripheral T-cell Lymphoma

October 5th 2016

​Steven M. Horwitz, MD, medical oncologist, Memorial Sloan Kettering, discusses the evolving role of CHOP in peripheral T-cell lymphoma. For years CHOP or a similar regimen has been the standard treatment for peripheral T-cell lymphoma.

Novel Agents Hold Significant Promise in Treatment of AML

October 1st 2016

Jessica K. Altman, MD, discussed the potential of agents poised to transform the landscape of acute myeloid leukemia.

Incorporating Generic Imatinib Into Frontline Treatment for CML

October 1st 2016

As generic imatinib enters the market, new questions focus on a renewed role for the agent in conjunction with second-generation TKIs.

Dr. Jerald Radich on Impact of Generic Imatinib in CML

October 1st 2016

​Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses the impact of the approval of generic imatinib in chronic myelogenous leukemia (CML).

Unmet Needs in Polycythemia Vera

September 29th 2016

Role of Ruxolitinib in Polycythemia Vera

September 29th 2016

Looking Beyond Hematocrit Control in Polycythemia Vera

September 29th 2016